

## North Yorkshire & York Area Prescribing Committee

Wednesday 7<sup>th</sup> June 2023  
2pm – 4.30pm, virtual meeting via Microsoft Teams

### Present

Name	Job Title	Organisation	Voting Member	Feb 2023	Mar 2023	Apr 2023	May 2023	Jun 2023
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Rachel Ainger	Y	Y	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Y	Y	Y	Y	Apols
Laura Angus	Head of Medicines Optimisation and Interim Chief Pharmacist at Humber, & North Yorkshire ICS	City of York Place	Y	Y	Y (from Item 15)	Faisal Majothi	Y	Y
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	City of York Place	Y	Y	Y	Apols	Apols	Apols
Dr William Ovenden	GP	City of York Place	Y	Y	Y	Y	Apols	Y
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Apols	Y	Y	Sara Moore
Dr Ben Walker (till Feb 2023)	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Apols	Victoria Millson	Victoria Millson	Apols	X
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Jane Crewe	Y	Y
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Apols	Y (from item 10)	Apols	X	X
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Apols	Y	Y	Y	Y
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Apols	Y	Apols	Y	Apols
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Apols	Kurt Ramsden	Kurt Ramsden	Kurt Ramsden	Apols
Anita Dobson	Public Health representative	City of York Council	Y	Y	Apols	Resigned		
Alison Levin	Finance representative	North Yorkshire Place	Y	Jo Horsfall	Jo Horsfall	Apols	Jo Horsfall	Jo Horsfall
Hazel Mitford	lay/patient representative		Y	Y	Apols	Apols	Y	Y
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Y	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire Place	N	Y	Y	Y	Y	Y
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Y	See above	Y	Y
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	See above	Y	Y
Sara Abbas-Llewelyn / Emily Parkes	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	N	X	X	Sara Abbas-Llewelyn	Sara Abbas-Llewelyn	Sara Abbas-Llewelyn
Ian Dean	LPC Representative		N	Y	Y	Y	Apols	Y
Dr Sally Tyrer	LMC Representative		N	X	X	X	Jane Raja	Jane Raja
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	For item 17	Y	Y	Apols	See above

The meeting was quorate with 8 out of 12 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Stuart Parkes.

## Part 1

### 1. **Apologies for absence and quoracy check**

Shaun O'Connell, Tim Rider, Kate Woodrow, Richard Morris, Angela Hall, Kurt Ramsden

### 2. **Declarations of interest**

#### **Declarations of interest:**

*The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.*

*Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.*

#### **Declarations of interest from today's meeting:**

*Nil declared.*

### 3. **Minutes of previous APC & decision summary of meeting held on 3<sup>rd</sup> May 2023**

The minutes of the May 2023 APC were approved as a true and accurate record subject to the following amendments:

- Item 18 – remove first line use from sentence as feeling sentence is too positive the way it is currently written.

### 4. **Outcome of items referred to May 2023 IPMOC**

Dexcom ONE and CGM – ongoing discussions at ICB as to cost implications for proposed updates to CGM policy in line with NICE guidance from March 2022 are moving forward a decision expected this month. APC confirmed the RAG status of Dexcom ONE and Freestyle Libre 2 as AMBER SR.

TA878 – paper gone to ICB board and working group being set up to look at ongoing provision once free central stocks are exhausted.

Items previously referred to IPMOC still awaiting confirmation of scheme of delegation for decision-making by IPMOC.

### 5. **Matters arising not on the agenda & declarations of AOB**

AOB – Xipamide discontinuation

HDFT Vulva treatment proforma – confirmed since last APC that these are being used in HDFT at present in the short term until nurses qualify as non-medical prescribers.

### 6. **Action log**

#### Dexcom ONE

Discussed under item 4.

#### Update on meeting of APC membership to help improve operation of the APC

Updated APC Terms of Reference to reflect these changes on today's agenda.

TA877: Finerenone for treating chronic kidney disease in type 2 diabetes

On today's agenda.

Faricimab (NICE TA 799 and 800) and Ranibizumab biosimilar update

KL has raised with HNY Eye Care Group and link with the ICB Executive Director of Clinical and Professional. ITEM NOW CLOSED.

Formulary Updates Approved at May 2023 APC

JC/SAL have updated Y&S and Harrogate formularies. ITEM NOW CLOSED.

**Outstanding actions from previous APC meetings**

Bicalutamide RAG status

Action still in progress.

Diazoxide for Chronic Intractable hypoglycaemia

KW/SM/JC to develop shared care guideline to be presented to future APC for approval.

Medical Devices Commissioning and Formulary Position

RDTTC to review previous MCC commissioning positions on individual medical devices in Q1 2023/24.

Oral minoxidil for androgenic alopecia

ICB policy alignment group have confirmed they will review this particular policy across the ICB when the NICE TA for baricitinib is published. Agreed no further action for item for APC until this policy is reviewed by the ICB.

Guidelines for recognition and management of non- IgE cow's milk allergy in children – partial update

CR has sought clarifications to p6 : Step 2-2 Re-challenge with cow's milk using iMAP guidelines after 4 weeks period (can be omitted when symptoms are severe) before guideline is returned to APC for approval.

Confirmed with authors that this that this exclusion is more for the exceptional case and allows some clinical judgement.

WO suggested some additional wording still need to be added to the guideline with the author. This is so guideline is stronger to support GPs with clarity on when not to rechallenge.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

**Part 2 – Governance**

**7. NY&Y APC terms of reference – updated**

Updated APC Terms of Reference were presented to and approved by the APC subject to suggested amendments being actioned.

**ACTION:**

- **RDTTC to update APC Terms of Reference and circulate final version.**

**Part 3 – Mental Health**

**8. Nil this month.**

## Part 4 – Formulary issues

### 9. Appeals against previous APC decisions

None received.

### 10. Formulary NICE TAs and MHRA Drug Safety Update – April 2023

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA880: Tezepelumab for treating severe asthma

All the above TAs are NHSE-commissioned and would therefore have no cost impact to the ICB.

### Medicines Safety MHRA Drug Safety Update – April 2023

The group noted the drug safety updates for April 2023. The links are to be added to the relevant sections of the formulary.

#### ACTION:

- **JC/SAL to update the formulary websites.**

### 11. Other formulary issues

Alfentanil injection for the management of moderate to severe pain in palliative care patients

A change on RAG status in Harrogate from RED to AMBER specialist recommendation to align with Y&S formulary was approved.

Clonidine patches for the treatment of dystonia in children

Approved a change in RAG status of clonidine patches to RED to align with West Yorkshire ICS.

TA877: Finerenone for treating chronic kidney disease in type 2 diabetes

The APC discussed the feedback from YSFT. It noted that expected patient numbers would be less than NICE estimated and the cost impact would fall within the delegated authority of the APC.

The APC agreed to add to the formulary as an AMBER SR drug with clarity around monitoring being provided in letters to GPs requesting them to prescribe for each patient. This status was based on it being a new drug, its drug interactions/contra-indications profile, and lack of clarity on NICE TA as to when to initiate in relation to other options.

#### ACTION:

- **JC/SAL to update the formulary websites.**

### 12. New Drug Applications

Tranexamic acid nose drops

Requested for Treatment of epistaxis in patients with Hereditary Haemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome).

The APC agreed to defer discussion to get clarity on the following:

- How it is administered and formulation that is used
- Evidence base
- Evidence and safety for long term prophylactic use
- Place in therapy vs tamoxifen or oral tranexamic acid

#### ACTION:

- **JC to seek further information from applicant.**

### 13. Compassionate use/free of charge scheme requests

Nil this month.

### 14. Endocrinology chapter review

The Endocrinology section is the next BNF chapter to be aligned across North Yorkshire.

There were a total of 316 drugs/devices listed in this section and 169 that did not have an absolute match.

The proposed recommendations were approved by the APC.

**ACTION:**

- **JC/SAL to update the formulary websites.**

**Part 5 – Shared Care and Guidelines (non-mental health)**

**15. Shared care guidelines for approval**

Nil this month.

**Part 6 – Other items of business**

**16. Addition of Buvidal to North Yorkshire and York Medicines Formulary (April 2023) - Further Information 3/5/2023 requested by the Area Prescribing Committee**

The following information was presented to the APC to answer the questions raised:

1. Emergency admission with suspected withdrawal symptoms from Buvidal

As a long-acting depot product with a wide dose window, presentation at A&E services in acute withdrawal is unlikely. The summary of product characteristics (SPC) advises as follows:

If Buvidal treatment is discontinued, its prolonged-release characteristics and any withdrawal symptoms experienced by the patient must be considered. If the patient is switched to treatment with sublingual buprenorphine, this should be done one week after the last weekly dose or one month after the last monthly dose of Buvidal according to the recommendations in the SPC.

2. Routine administration as part of an in-patient episode

The treatment window for the 7-day depot injection is +/- 2 days, and the 28-day product is +/- 7 days. In planned admission, specialist services should liaise with service users to arrange administration around the admission where possible. Where this is not possible, or the admission is unplanned, the SPC advises as follows for avoiding missed doses:

To avoid missed doses, the weekly dose may be administered up to 2 days before or after the weekly time point, and the monthly dose may be administered up to 1 week before or after the monthly time point.

3. Administration advice for clinicians

Buvidal is administered via subcutaneous injection. Further information on preparation, administration and disposal is available in section 6.6 of the SPC.

The APC agreed to add this information to the formulary.

**17. NHSE Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets**

A national assessment programme of blood glucose and ketone meters, testing strips and lancets concluded in February this year with the publication of the enclosed commissioning recommendations.

The recommended meters, strips and lancets have passed a rigorous evaluation process ensuring that only the best of the highest quality and, cost-effective devices are approved.

Across North Yorkshire and York our existing guidelines recommend the following:

Type 2 Diabetes;

➤ First choice: Finetest Lite

➤ Second choice: GlucoRx Nexus

Type 1 Diabetes:

➤ GlucoRx HCT & Ketone

All three of the above are included in the national document.

It is expected that all ICBs consider local recommendations for both primary and secondary care based upon the commissioning recommendations set out in the document. The APC noted that working group across the ICB has been set up to do this and the APC awaits its outputs.

**18. Glucagen® supply problem – June 2023**

APC noted the recently issued medicines supply notification for Glucagen® which will be unavailable from mid-June 2023 to mid-July 2023.

There are two glucagon preparations available – GlucaGen® (1mg powder for injection kit) and Ogluo® (0.5mg and 1mg pre-filled auto-injector pens)

GlucaGen® 1mg powder for injection kit will be unavailable from mid-June 2023 until to mid-July (a period of 4 weeks).

Ogluo® 0.5mg and 1mg pre-filled auto-injector pens can be used for the treatment of severe hypoglycaemic episodes; however, is not suitable for treatment of beta blocker or other drug overdoses. Ogluo® is not currently on the Y&S and Harrogate formularies.

In November 2022 the APC refused the formulary application for Ogluo® on the basis of significant cost difference over current Glucagen® product and no defined cohort of patients who would benefit the most presented in the application. This decision is based on the evidence submitted to date to the APC by the applicant.

The APC agreed no need to add Ogluo® to formulary but prescribers could refer to the medicines supply notification if a supply of GlucaGen® was unavailable on a patient-by-patient basis.

**Part 7 – Standing items (for information only)**

**19. IPMOC minutes – April 2023**

Circulated for information.

**20. TEWV D&T minutes – March 2023**

Not yet available.

**21. York & Scarborough Trust Drug and Therapeutics Committee minutes – March 2023**

Circulated for information.

**22. Harrogate Trust Medicines and Therapeutics Group minutes – since September 2022**

Not yet available.

**23. County Durham & Tees Valley APC minutes – March and May 2023**

Circulated for information.

**24. West Yorkshire ICS APC Minutes – March 2023**

Circulated for information.

**25. Humber APC minutes – May 2023**

Not yet available.

**26. Humber APC decisions & recommendations – May 2023**

Not yet available.

**27. RDTC Monthly Horizon scanning – May 2023**

Circulated for information.

**28. NENC Medicines Committee decision Summary – April 2023**

Circulated for information.

**Any Other Business**

Xipamide discontinuation

The APC has received reports that xipamide has been discontinued. It agreed to confirm with manufacturer if this is correct and discuss alternative outside of the APC ahead of full discussion if confirmed it is discontinued at July 2023 APC.

Formulary applications received for July 2023 meeting

The APC have received the following formulary applications to date for the July 2023 APC meeting:

- Nil to date.

**Date and time of next meeting**

Wednesday 5<sup>th</sup> July 2023, 2pm – 4.30pm, virtual meeting via Microsoft Teams